This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Situ, H.
Right arrow Articles by Bobek, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Situ, H.
Right arrow Articles by Bobek, L. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2000, p. 1485-1493, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Assessment of Antifungal Therapeutic Potential of Salivary Histatin-5, Two Variants of Histatin-5, and Salivary Mucin (MUC7) Domain 1

Hongsa Situ and Libuse A. Bobek*

Department of Oral Biology, State University of New York at Buffalo, Buffalo, New York 14214

Received 29 October 1999/Returned for modification 10 December 1999/Accepted 6 March 2000

Human salivary histatin-5 (Hsn-5) is a 24-residue peptide that possesses potent antifungal activity in vitro. The MUC7 gene encodes human salivary low-molecular-weight mucin (MG2). The candidacidal activity of MUC7 domain 1 (MUC7 D1, the N-terminal 51 amino acid residues of MUC7) in vitro has also been demonstrated. In this study, we have investigated the antifungal therapeutic potential of Hsn-5, its two variants, R12I/K17N and R12I/H21L, and MUC7 D1. First, these peptides were tested for activities against different clinically important fungi. We found them to possess broad-spectrum antifungal activities; specifically, most exhibited excellent in vitro activity against eight clinically important fungal strains tested, including Candida albicans and Candida glabrata and their azole-resistant counterparts and Cryptococcus neoformans and its amphotericin B-resistant counterpart. These findings also suggest that the mechanism of action of both Hsn-5 and MUC7 D1 for these fungi is different from that of amphotericin B or azole antifungal agents. Second, we examined the stability of these peptides in whole human saliva and human serum. In saliva, the Hsn-5 variants R12I/K17N and R12I/H21L and MUC7 D1 degraded at a lower rate than Hsn-5. In human serum, MUC7 D1 was also more stable than Hsn-5; both peptides were more stable in serum than in saliva. Third, we examined the cytotoxicity of these peptides using human erythrocytes and two human cell lines (KB and HSG). No (or very low) hemolytic activity was observed with any of the four peptides, even at the highest protein concentration tested (200 µM), while amphotericin B caused 100% hemolysis at only 12.5 µM. The toxic effects of Hsn-5 and MUC7 D1 toward KB and HSG cells were also much lower than that of amphotericin B as measured by trypan blue exclusion. Together, these findings indicate that the investigated peptides possess high antifungal therapeutic potential, in particular for the treatment of drug-resistant fungal strains associated with immunocompromised (particularly human immunodeficiency virus-infected) patients. The same peptides could also be used as components of artificial saliva for patients with salivary dysfunction.

* Corresponding author. Mailing address: Department of Oral Biology, State University of New York at Buffalo, 109 Foster Hall, 3435 Main St., Buffalo, NY 14214-3092. Phone: (716) 829-2465. Fax: (716) 829-3942. E-mail: libuse_bobek{at}sdm.buffalo.edu.

Antimicrobial Agents and Chemotherapy, June 2000, p. 1485-1493, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Li, L., Redding, S., Dongari-Bagtzoglou, A. (2007). Candida glabrata, an Emerging Oral Opportunistic Pathogen. JDR 86: 204-215 [Abstract] [Full Text]  
  • Wei, G.-X., Campagna, A. N., Bobek, L. A. (2006). Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm. J Antimicrob Chemother 57: 1100-1109 [Abstract] [Full Text]  
  • Viejo-Diaz, M., Andres, M. T., Fierro, J. F. (2005). Different Anti-Candida Activities of Two Human Lactoferrin-Derived Peptides, Lfpep and Kaliocin-1. Antimicrob. Agents Chemother. 49: 2583-2588 [Abstract] [Full Text]  
  • Wei, G.-X., Bobek, L. A. (2005). Human Salivary Mucin MUC7 12-Mer-L and 12-Mer-D Peptides: Antifungal Activity in Saliva, Enhancement of Activity with Protease Inhibitor Cocktail or EDTA, and Cytotoxicity to Human Cells. Antimicrob. Agents Chemother. 49: 2336-2342 [Abstract] [Full Text]  
  • Wei, G.-X., Bobek, L. A. (2004). In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole. J Antimicrob Chemother 53: 750-758 [Abstract] [Full Text]  
  • Paulsen, F. P., Corfield, A. P., Hinz, M., Hoffmann, W., Schaudig, U., Thale, A. B., Berry, M. (2003). Characterization of Mucins in Human Lacrimal Sac and Nasolacrimal Duct. IOVS 44: 1807-1813 [Abstract] [Full Text]  
  • Bobek, L. A., Situ, H. (2003). MUC7 20-Mer: Investigation of Antimicrobial Activity, Secondary Structure, and Possible Mechanism of Antifungal Action. Antimicrob. Agents Chemother. 47: 643-652 [Abstract] [Full Text]  
  • Fitzgerald, D. H., Coleman, D. C., O'Connell, B. C. (2003). Susceptibility of Candida dubliniensis to Salivary Histatin 3. Antimicrob. Agents Chemother. 47: 70-76 [Abstract] [Full Text]  
  • Edgerton, M., Koshlukova, S. E., Araujo, M. W. B., Patel, R. C., Dong, J., Bruenn, J. A. (2000). Salivary Histatin 5 and Human Neutrophil Defensin 1 Kill Candida albicans via Shared Pathways. Antimicrob. Agents Chemother. 44: 3310-3316 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»